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INTRODUCTION
Dengue is caused by four flavivirus serotypes (DEN-1,DEN-2, DEN-3 and DEN-4). The incidence of dengue
fever (DF) and dengue hemorrhagic fever (DHF) has increased
thirty-fold globally in the last four decades and more than
half the world’s population (including developed countries)
is now threatened with infection from dengue virus.1
Epidemiological evidence shows that DHF and dengue shock
syndrome (DSS), the more serious manifestations of the
disease, occur more frequently on re-infection with a second
serotype. The co-circulation of multiple serotypes has also
been reported from many countries.2 The situation in India is
reflected by the occurrence of major disease outbreaks in
India from time to time over the last few decades.3,4 However,
no reliable data are available to assess the magnitude of the
disease in our country. But, obviously, the situation is not
very encouraging. In the last seven years, there have been
two major disease outbreaks of dengue in north India.5
CLINICAL FEATURES
DF is an acute viral disease manifesting with myalgias,
headache, retro-orbital pain, vomiting, maculopapular rash,
leucopenia and thrombocytopenia. DHF is characterized by
four major clinical features: high fever, hemorrhagic
phenomena, hepatomegaly and signs of impending
circulatory failure (postural hypotension, resting tachycardia,
diaphoresis). Significant thrombocytopenia with concurrent
hemoconcentration is a typical laboratory manifestation of
DHF. However, in interpreting hematocrit, the potential effect
of pre-existing anemia, severe hemorrhage and dehydration
needs to be taken into consideration.
The major pathophysiological abnormality differentiating
DF from DHF is the plasma leakage syndrome
(hemoconcentration, hypoproteinemia and/or serous
effusion). In fact, the severity of disease in DHF depends on
the quantum of plasma leakage. The patients of DHF
presenting with shock due to excessive plasma loss are labeled
as dengue shock syndrome (DSS). DHF/DSS are potentially
fatal conditions.
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The clinicians should be aware of the unusual
presentations of DF/DHF. The disease may present as acute
acalculous cholecystitis, hepatitis, fulminant hepatic failure,
edematous gall bladder wall on ultrasonography, serositis,
acute renal failure and neurological manifestations including
intracranial bleeding, seizures and myelitis.6-10 The serositis
of dengue involves the pleural and abdominal cavity.
TRANSMISSION OF DENGUE VIRUS
Over the last few decades, the earlier principal vector of
dengue virus in Asia, Aedes albopictus has been replaced by
Aedes aegypti. Interestingly, Aedes aegypti has been
described as having a relatively low oral receptivity for dengue
virus as compared to Aedes albopictus.11 However, it has
been recently documented that oral receptivity of Aedes
aegypti to DEN-2 virus is significantly more than Aedes
albopictus. Moreover, the infectivity of southeast (SE) Asian
genotype of dengue virus vis-à-vis American genotype has
also intrigued investigators and it has been suggested that
Aedes aegypti tends to be more susceptible to infection by
DEN-2 virus of SE Asian genotype as compared to American
genotype.12 These observations obviously have important
epidemiological implications for Asian countries as the local
vector has increased propensity to transmit dengue infection,
especially DEN-2 (relatively more virulent serotype).
Different serotypes have been observed in 1996 (DEN-
2)13 and 2003 (DEN-3 and 2)5 outbreaks in north India. The
change in serotypes underscores the role of viral genetic
turnover within a focal population and the potential
importance of adaptive evolution in viral epidemic expansion.
In fact, the mortality observed in 1996 was far greater than
the recent outbreak and possibly can be explained by the
difference in the serotypes (DEN-2 is more virulent than DEN-
3).
PATHOGENESIS
Various studies of the pathogenesis of DHF have
documented the importance of initial high levels of virus
replication during acute febrile phase. However, the possible
association of viremia during the transition from fever to
defervescence, a critical stage in determining the severity of
disease, is also being appreciated. It has been observed that
there are higher levels of plasma dengue viral RNA in DHF
patients as compared to DF patients during the acute febrile
stage. Although, during defervescence, the level of plasma
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dengue viral RNA is undetectable in most DF patients, it
remains significantly high in all DHF patients. It is being
suggested that measurement of increased level of plasma
dengue viral RNA during defervescence may serve as a
disease marker for DHF in the future.14
Animal models infected with DEN-2 have several
similarities to human DEN-2 infection.15 The most notable
cytokine amplification is observed with tumor necrosis factor-
alpha (TNF-α). In animal models, treatment with anti-TNF-α
serum has been demonstrated to reduce mortality rate
significantly. A similar analogy has been tried in human
beings, but with limited success. In fact, studies have
observed that increase in TNF-α correlates with hemorrhagic
manifestations and the increase in interleukin-10 with
thrombocytopenia.16 It has also been observed that anti-
platelet IgM levels are higher in DHF/DSS than in DF patients.
Moreover, platelet-associated IgG (PAIgG) formation
involving anti-dengue virus IgG also plays a pivotal role in
the induction of transient thrombocytopenia during the acute
phase of secondary dengue virus infection.17
Interestingly, acute-phase serum samples obtained from
patients of human immunodeficiency virus (HIV) co-infected
with dengue virus show reduced HIV infectivity suggesting
the possibility that HIV replication is suppressed during acute
dengue fever, as occurs during hepatitis GB infection, scrub
typhus infection and measles.18,19 Interestingly, it has also
been documented that the African black population have a
gene providing nearly complete protection against severe
dengue illness.20 The significance of these observations needs
further investigation.
MANAGEMENT
Hydration
The conventional management principles of DF/DHF
include rehydration therapy (preferably oral and/or
intravenous replacement in hospitalized patients), control of
high fever by sponging and paracetamol (non-steroidal anti-
inflammatory drugs are absolutely contraindicated due to
bleeding diathesis).21 In fact, oral rehydration therapy (ORT)
should be initiated on the first day of the illness in DF as it
prevents DHF and decreases risk for hospitalization in these
patients.22
Platelet Transfusion
The role of platelet transfusion as a panacea for the
management of dengue needs special mention. In fact, the
platelet count is not predictive of bleeding. The duration of
shock and low-normal hematocrit at the time of shock are risk
factors of severe hemorrhage and subsequent mortality.23
However, theoretically, thrombocytopenia is a risk factor for
hemorrhage and the threshold for prophylactic platelet
transfusion is 10,000/mm3 in non-dengue patients.24 It can be
suggested that since there is no other specific therapy for
DHF/DSS, patients with bleeding tendency and/or a platelet
count less than 20,000-25,000/mm3 may be empirically
transfused platelets. It has been documented that non-dengue
patients receiving multiple transfusions may be alloimmunized
to many HLA- and platelet-specific antigens and demonstrate
no increase in their post-transfusion platelet count. In dengue
patients, this trend may be all the more evident in view of the
other factors contributing to thrombocytopenia. Therefore,
dengue patients should preferably receive single donor
apheresis platelets (SDAP) as compared to random donor
platelets (RDP) to lower the risk of alloimmunization.24
Unfortunately, patients as well as health care workers tend
to “chase” platelet counts. As discussed earlier, the crux in
treatment of dengue patients is maintenance of good
hydration, monitoring for any overt bleeding and not “panic”
if the platelet count is more than 50,000/mm3 but less than
150,000/mm3 (normal platelet count is 150,00-450,000/mm3). In
fact, most of these patients are recovering from DF viz.
patients are afebrile, appetite is normal and have a feeling of
well being, but the platelet count is on the “lower side”. This
“syndrome” of chasing platelet count in dengue patients
who are otherwise completely asymptomatic and improving
can be labeled as “Dengue panic syndrome”. This panic
syndrome was quite evident in the outbreak of dengue in
northern states of India in 2003. Therefore, the role of media
and health care workers in dissemination of the simple
strategy of hydration from day one of the illness needs to be
emphasized. It will not be an exaggeration to state that
appropriate hydration is the only therapeutic modality that
makes the difference between life and death in dengue patient.
The flip side of the “dengue panic syndrome” is the
overloading of the already strained emergency services of
tertiary care hospitals by these patients. Consequently, the
“true” DHF/DSS patients needing urgent attention in the
emergency may not get the desired care, in spite of the best
efforts of the hospital personnel.25
Ancillary Therapeutic Modalities
The newer strategies (supportive and pharmacological)
are also being tried to combat the mortality associated with
DHF/DSS. The patients with DSS may develop acute
respiratory distress syndrome (ARDS). This was also
observed during the recent outbreak in north India. Previously,
these patients were treated with oxygen through a nasal
cannula and/or tracheal intubation and mechanical
ventilation, as necessary. A recent study has proposed the
role of non-invasive ventilation in improving the morbidity
and mortality of ARDS in children with DHF/DSS in dengue-
endemic areas.26 The role of mycophenolic acid (MPA), an
immunosuppressive agent, is also being investigated in the
treatment of dengue.27
PREVENTION
Obviously, the core strategy for the reduction in
transmission of dengue is the role of community participation
in vector control. Aedes aegypti feeds during the day, rests
indoors and lays its eggs in artificial water containers.
Therefore, vector control includes simple measures like
eliminating larval habitats, using insect repellents/indoor
space-spray insecticides and mosquito nets while sleeping.
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The widespread use of chemical insecticides over the years
has exposed Aedes mosquito to an intense selection pressure
of resistance against these compounds. Therefore, programs
will have to be designed to monitor the resistance of Aedes
aegypti to insecticides in our country. This assumes greater
importance now as dengue is rapidly emerging as a major
threat to public health in India and an effective dengue
vaccine is still eluding us.
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